BioArctic AB said on Monday it has entered a research and collaboration agreement with Eli Lilly and Company to create a new drug candidate that combines BioArctic’s BrainTransporter delivery system with a Lilly proprietary molecule targeting neurodegenerative disease. Following the announcement BioArctic shares rose by more than 2%.
Under the terms announced by the Stockholm-based company, BioArctic will receive an upfront payment of $30 million. The agreement also makes BioArctic eligible for additional milestone payments totaling up to $770 million, plus tiered mid-single digit royalties on any future global product sales if the candidate reaches the market.
The collaboration assigns BioArctic responsibility for generating the combined drug candidate by applying its BrainTransporter technology to a Lilly-owned compound. Lilly will assume full responsibility for subsequent global development and commercialization of the candidate and related products, according to BioArctic.
Company statement
In a prepared statement cited by BioArctic, CEO Gunilla Osswald said she was pleased that a major pharmaceutical company recognized the potential of the BrainTransporter platform. The statement emphasized a shared goal with Lilly to advance treatments for severe neurological disorders and framed the collaboration as evidence of that alignment.
Platform context and prior collaborations
This is the fourth collaboration in which BioArctic has applied the BrainTransporter technology with external partners. The company noted prior arrangements including a research evaluation on BAN2802 with Eisai, a global license agreement with Bristol Myers Squibb for its PyroGlutamate-amyloid-beta antibody program, and an option, collaboration and license agreement with Novartis.
BioArctic also confirmed that it retains the right to use the BrainTransporter platform outside the scope of these four agreements. The company positions the platform as applicable across multiple therapeutic areas for transporting biologics and other modalities into the brain.
How the technology works
According to BioArctic, the BrainTransporter technology facilitates the passage of drugs into the brain via the transferrin receptor. The company says active transport across the blood-brain barrier enabled by this approach can achieve broader brain distribution, which has the potential to improve efficacy, produce a better safety profile, and deliver more convenient dosing.
Product heritage
BioArctic is also credited with inventing lecanemab, marketed as Leqembi, which the company describes as the first drug demonstrated to slow disease progression and reduce cognitive impairment in early Alzheimer’s disease. Leqembi was developed in collaboration with Eisai; Eisai handles regulatory interactions and global commercialization for that product.
- Financial terms: $30 million upfront, up to $770 million in milestones, and tiered mid-single digit royalties.
- Roles: BioArctic will create the combined candidate; Lilly will lead global development and commercialization.
- Technology: BrainTransporter uses the transferrin receptor to ferry biologics across the blood-brain barrier.
The deal reinforces BioArctic’s strategy of pairing its delivery platform with external therapeutic programs while preserving rights to deploy BrainTransporter more broadly. Lilly’s role as the downstream developer and commercializer shifts late-stage clinical and market risks to Lilly, while BioArctic stands to gain near-term funding plus milestone and royalty upside if the program advances.